还原叶酸载体基因甲基化和甲氨蝶呤耐药的关系  

Relationship between reduced folate carrier gene methylation and methotrexate resistance

作　　者：李珊珊[1] 张娜[1] 蒋慧[1] 

机构地区：[1]上海交通大学附属儿童医院上海市儿童医院血液肿瘤科,200040

出　　处：《国际儿科学杂志》2014年第3期267-270,共4页International Journal of Pediatrics

基　　金：上海市卫生局青年科研项目（20114y068）

摘　　要：肿瘤复发及耐药严重影响肿瘤患者的治疗效果和预后.近年来研究发现,表观遗传修饰参与肿瘤耐药的产生.DNA甲基化是表观遗传的方式之一,药物代谢酶基因DNA出现甲基化可影响基因的表达,导致耐药的出现.抗肿瘤药物甲氨蝶呤（methotrexate,MTX）是一种应用最为广泛的抗叶酸代谢药,用于治疗白血病、骨肉瘤、头颈癌等恶性肿瘤.还原叶酸载体（reduced folate carrier,RFC）是MTX主要的转运载体,该基因的甲基化与肿瘤细胞对MTX耐药相关.该文以RFC的作用、RFC基因甲基化与MTX耐药、RFC甲基化的影响因素等方面作一综述.Tumor recurrence and drug resistance impact patients＇therapeutic effect and prognosis seri- ously. In recent years, it has been found that epigenetic changes are involved in drug resistance. DNA methylation is one of the ways of epigenetic. DNA methylation of drug metabolism enzyme gene can affect gene＇s expres- sion, leading to drug resistance. Methotrexate（ MTX）, a folic acid antagonist,is the most widely used drug in the treatment of malignant tumors, such as leukemia, osteosarcoma, head and neck cancer, and so on. Reduced folate carder（RFC） is the main transporter carrier of MTX,and gene methylation is related to tumor cells＇resistance to MTX. This paper reviews the role of RFC,relation of RFC methylation and methotrexate resistance and the fac- tors of RFC methylation.

关 键 词：表观遗传 还原叶酸载体 甲基化 甲氨蝶呤 耐药 

分 类 号：R730.5[医药卫生—肿瘤]